Table 2.

Humanized mice models for EBV vaccines.

Year	Vaccine formulation and immunization route	Challenge strain	Results	Ref.
2008	αDEC-205-EBNA-1(aa400-641) + poly(I:C) i.p. twice at one month interval	None	EBNA-1 specific T cells and anti-EBNA-1 antibodies were detected	95
2015	rAd5F35/BZLF-1-transduced human DCs i.p. once or twice at a 2-week interval	NoneA	Prolonged survival to EBV-LPD	98
2018	immunogenic particles containing EBNA-1 + poly(I:C) i.p. twice at a 4-week interval	B95-8	Significant protection against EBV challenge	104
2022	Passive infusion of antibodies purified from mice immunized with gH/gL/gp42 + gp350D123 or gH/gL + gp350D123 ferritin nanoparticles 20 µg of mIgG per gram of mouse i.p. at day −1, day 0, and day 1	B95-8	Only one of six mice in each group received immune IgG had transient low-level viremia	88
2022	Passive infusion of antibodies purified from mice immunized with gH/gL 60 mer nanoparticle 500 mg of total IgG per mouse i.p. 48 h pre EBV challenge	B95-8	Purified antibodies from immunized mice protected humanized mice from lethal EBV challenge	86

αDEC-205-EBNA-1 C-terminus of EBNA-1 fused with DEC-205 (a human endocytic receptor), None there is no challenge experiment. i.p. intraperitoneally, DCs dendritic cells. EBV-LPD EBV-associated lymphoproliferative diseases.

^Ahumanized mice reconstituted with cells from an EBV-seropositive donor was used in this study.